Drug resistance evolution of a Mycobacterium tuberculosis strain from a noncompliant patient

被引:31
作者
Meacci, F
Orrù, G
Iona, E
Giannoni, F
Piersimoni, C
Pozzi, G
Fattorini, L
Oggioni, MR
机构
[1] Univ Siena, Policlin Le Scotte, LAMMB, Dipartimento Biol Mol, I-53100 Siena, Italy
[2] Univ Cagliari, Dipartimento Sci Odontostomatol, I-09124 Cagliari, Italy
[3] Ist Super Sanita, Dipartimento Malattie Infett Parassitaire & Immun, I-00161 Rome, Italy
[4] Osped Riuniti Bergamo, Dipartimento Microbiol Clin, Ancona, Italy
关键词
D O I
10.1128/JCM.43.7.3114-3120.2005
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
The emergence and spread of multidrug-resistant (MDR) Mycobacterium tuberculosis (MT) represents a worldwide health care problem because of the difficulty in treating these infections. Development of drug resistance in MT arises mainly by mutation of chromosomal genes. To investigate the evolution of a NIT population during a long-lasting infection, the phenotypic and genotypic changes in the drug resistance of 10 sequential MT isolates from a noncompliant chronically infected patient were investigated. During more than 12 years of active disease, a MDR population developed; molecular typing showed one single parental strain that infected the patient and persisted throughout the disease. Molecular analysis of the drug resistance-related genes revealed that discrete subpopulations evolved over time from the parental strain by acquiring and accumulating resistance-conferring mutations to isoniazid, rifampin, and streptomycin. Overall, these observations indicate that during a chronic infection, several subpopulations may coexist in the same patient with different drug susceptibility profiles.
引用
收藏
页码:3114 / 3120
页数:7
相关论文
共 40 条
[21]   Detection of resistance to isoniazid, rifampin, and streptomycin in clinical isolates of Mycobacterium tuberculosis by molecular methods [J].
Nachamkin, I ;
Kang, C ;
Weinstein, MP .
CLINICAL INFECTIOUS DISEASES, 1997, 24 (05) :894-900
[22]  
*NATL COMM CLIN LA, 2003, SUSC TEST MYC NOC OT, V23
[23]   Double infection with a resistant and a multidrug-resistant strain of Mycobacterium tuberculosis [J].
Niemann, S ;
Richter, E ;
Rüsch-Gerdes, S ;
Schlaak, M ;
Greinert, U .
EMERGING INFECTIOUS DISEASES, 2000, 6 (05) :548-551
[24]   Protocol for real-time PCR identification of anthrax spores from nasal swabs after broth enrichment [J].
Oggioni, MR ;
Meacci, F ;
Carattoli, A ;
Ciervo, A ;
Orru, G ;
Cassone, A ;
Pozzi, G .
JOURNAL OF CLINICAL MICROBIOLOGY, 2002, 40 (11) :3956-3963
[25]   Genetic polymorphism in Mycobacterium tuberculosis isolates from patients with chronic multidrug-resistant tuberculosis [J].
Post, FA ;
Willcox, PA ;
Mathema, B ;
Steyn, LM ;
Shean, K ;
Ramaswamy, SV ;
Graviss, EA ;
Shashkina, E ;
Kreiswirth, BN ;
Kaplan, G .
JOURNAL OF INFECTIOUS DISEASES, 2004, 190 (01) :99-106
[26]   rpoB mutations in multidrug-resistant strains of Mycobacterium tuberculosis isolated in Italy [J].
Pozzi, G ;
Meloni, M ;
Iona, E ;
Orrù, G ;
Thoresen, OF ;
Ricci, ML ;
Oggioni, MR ;
Fattorini, L ;
Orefici, G .
JOURNAL OF CLINICAL MICROBIOLOGY, 1999, 37 (04) :1197-1199
[27]  
Rinder H, 2001, INT J TUBERC LUNG D, V5, P339
[28]   Culture-independent prediction of isoniazid resistance in Mycobacterium tuberculosis by katG gene analysis directly from sputum samples [J].
Rinder, H ;
Feldmann, K ;
Tortoli, E ;
Grosset, J ;
Casal, M ;
Richter, E ;
Rifai, M ;
Jarlier, V ;
Vaquero, M ;
Rüsch-Gerdes, S ;
Cambau, E ;
Gutierrez, J ;
Löscher, T .
MOLECULAR DIAGNOSIS, 1999, 4 (02) :145-152
[29]   Fitness cost of chromosomal drug resistance-conferring mutations [J].
Sander, P ;
Springer, B ;
Prammananan, T ;
Sturmfels, A ;
Kappler, M ;
Pletschette, M ;
Böttger, EC .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2002, 46 (05) :1204-1211
[30]   Compensatory ahpC gene expression in isoniazid-resistant Mycobacterium tuberculosis [J].
Sherman, DR ;
Mdluli, K ;
Hickey, MJ ;
Arain, TM ;
Morris, SL ;
Barry, CE ;
Stover, CK .
SCIENCE, 1996, 272 (5268) :1641-1643